Compare Merck & Co., Inc. (MRK) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Palantir Technologies Inc — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while Palantir Technologies Inc trades at $200.24 (market cap $477.68B). The key difference: Palantir Technologies Inc is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Palantir Technologies Inc for 78 Days on average.
| MRK | PLTR | |
|---|---|---|
Market Cap | $351.28B | $477.68B |
Volume | 7,969,665 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $156.43 | $207.18 |
52-Week Low | $82.49 | $107.27 |
Typical Hold Time | 98 Days | 78 Days |
Enterprise Value | $398.04B | $468.48B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Palantir (PLTR) trades at $194.04, up 1.02% today, near its recent high and above the consensus price target of $191.69. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company reported robust revenue of $4.48 billion in 2025, with net income surging to $1.63 billion and a net margin of 36.3%, while recent quarters have consistently beaten EPS expectations.
Outlook remains positive driven by AI platform growth and expanding commercial customer base, but high valuation ratios (P/E of 169.9, P/S of 83.02) pose risks. Investor sentiment is buoyed by analyst buy ratings (53.84%) and partnerships like the recent Armada alliance, though competitive pressures and execution challenges are key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
